3',5'-dibenzoyl-2'-deoxy-β-L-uridine | 31615-99-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 3',5'-dibenzoyl-2'-deoxy-β-L-uridine
• 英文别名: 3',5'-di-O-benzoyl-2'-deoxy-L-uridine；3',5'-di-benzoyl-2'-deoxy-L-uridine；1-(3,5-di-O-benzoyl-2-deoxy-β-L-erythro-pentofuranosyl)uracil；3',5'-Di-O-benzoyl-2'-deoxy-L-uridin；((2S,3R,5S)-3-(benzoyloxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl benzoate；[(2S,3R,5S)-3-benzoyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl benzoate
• CAS: 31615-99-3
• 化学式: C₂₃H₂₀N₂O₇
• 分子量: 436.421
• InChiKey: WTTRUBICDWFROZ-HBFSDRIKSA-N

物化性质

• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3',5'-dibenzoyl-2'-deoxy-β-L-uridine 在 吡啶 、 ammonium hydroxide 、 N,O-双三甲硅基乙酰胺 、 三氟甲磺酸三甲基硅酯 作用下， 反应 28.5h， 生成 2'-deoxyguanosine
  参考文献：
  名称：

  L-Thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth

  摘要：

  We have demonstrated that herpes simplex 1 (HSV1) thymidine kinase (TK) shows no stereospecificity for D- and L-beta-nucleosides. In vitro, L enantiomers are not recognized by human TK, but function as specific substrates for the viral enzyme in the order: L-thymidine (L-T) much greater than 2'-deoxy-L-guanosine (L-dG) > 2'-deoxy-L-uridine (L-dU) > 2'-deoxy-L-cytidine (L-dC) > 2'-deoxy-L-adenosine (L-dA). HSV1 TK phosphorylates both thymidine enantiomers to their corresponding monophosphates with identical efficiency and the K(i) of L-T (2 muM) is almost identical to the K(m) for the natural substrate D-T (2.8 muM). The L enantiomer reduces the incorporation of exogenous [H-3]T into cellular DNA in HeLa TK-/HSV1 TK+ but not in wild-type HeLa cells, without affecting RNA, protein synthesis, cell growth, and viability. L-T markedly reduces HSV1 multiplication in HeLa cells. Our observations could lead to the development of a novel class of antiviral drugs characterized by low toxicity.

  DOI：

  10.1021/jm00100a029
• 作为产物：
  描述：

  3',5'-di-O-benzoyl-2'-chloro-2'-deoxy-L-uridine 在 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 苯 为溶剂， 反应 1.5h， 以95%的产率得到3',5'-dibenzoyl-2'-deoxy-β-L-uridine
  参考文献：
  名称：

  对映选择性合成和生物评价的5-邻氨基甲酰基嘧啶核苷。

  摘要：

  当与中子结合时，碱修饰的含碳硼烷的核苷，例如5-o-碳硼烷基-2'-脱氧尿苷（CDU），具有治疗某些恶性肿瘤的潜力。对于用于脑肿瘤和其他恶性肿瘤的硼中子捕获疗法（BNCT）中使用的修饰核苷，各种细胞中缺乏毒性，癌细胞中的高积累和细胞内磷酸化是理想的特性。这项工作的目的是合成几种含5-o-碳烷基的核苷的两个β-对映体。这些衍生物可具有有利的性质，例如高亲脂性，高运输性，被磷酸化的能力以及对分解代谢的抵抗力。还合成了2'，3'-二羟基核苷的β-异构体和糖部分含杂原子的类似物。碳硼烷基嘧啶核苷可以由母体β-D-核苷，β-L-核苷或通过偶联反应制备。二氧戊环衍生物7是通过受保护的5-o-碳氧烷基尿嘧啶（8，CU）与相应的受保护的杂环之间的偶联反应制备的。在N-糖基化过程中使用了特定的催化剂以促进β-异构体的形成。这些新的手性5-o-碳硼烷基嘧啶衍生物的生物学评估表明，这些化合物中的大多数在多种正常

  DOI：

  10.1016/s0968-0896(99)00222-9

文献信息

• Synthesis of beta-L-2'-deoxy nucleosides
  申请人：Storer Richard

  公开号：US20050059632A1

  公开（公告）日：2005-03-17

  An improved process for the preparation of 2′-modified nucleosides and 2′-deoxy-nucleosides, such as, β-L-2′-deoxy-thymidine (LdT), is provided. In particular, the improved process is directed to the synthesis of a 2′-deoxynucleoside that may utilize different starting materials but that proceeds via a chloro-sugar intermediate or via a 2,2′-anhydro-1-furanosyl-nucleobase intermediate. Where an 2,2′-anhydro- 1 -furanosyl base intermediate is utilized, a reducing agent, such as Red-Al, and a sequestering agent, such as 15-crown-5 ether, that cause an intramolecular displacement reaction and formation of the desired nucleoside product in good yields are employed. An alternative process of the present invention utilizes a 2,2′-anhydro-1-furanosyl base intermediate without a sequestering agent to afford 2′-deoxynucleosides in good yields. The compounds made according to the present invention may be used as intermediates in the preparation of other nucleoside analogues, or may be used directly as antiviral and/or antineoplastic agents.

  提供了一种改进的2'-改性核苷和2'-脱氧核苷的制备工艺，例如，β-L-2'-脱氧胸苷（LdT）。特别是，改进的工艺针对的是2'-脱氧核苷的合成，该合成可能使用不同的起始材料，但都通过氯糖中间体或通过2,2'-脱水-1-呋喃糖核苷中间体进行。当使用2,2'-脱水-1-呋喃糖碱基中间体时，会采用还原剂（如Red-Al）和隔离剂（如15-冠-5醚），它们能引起分子内位移反应，并形成所需核苷产品的高收率。本发明的一种替代工艺使用2,2'-脱水-1-呋喃糖碱基中间体而不使用隔离剂，也能以高收率获得2'-脱氧核苷。根据本发明制成的化合物可以作为制备其他核苷类似物的中间体，或者可以直接用作抗病毒和/或抗肿瘤剂。
• Methods of manufacture of 2'-deoxy-beta-L-nucleosides
  申请人：——

  公开号：US20040266996A1

  公开（公告）日：2004-12-30

  The present invention relates to the synthesis of 2′-deoxy-&bgr;-L-thymidine, 2′-deoxy-&bgr;-L-uridine and 2′-deoxy-&bgr;-L-cytidine, and their derivatives, such as the 3′-O-acyl or 3′,5′-O-diacyl prodrugs, including the 3′-O-L-aminoacyl and 3′,5′-O-L-diaminoacyl prodrugs, and particularly the 3′-O-L-valinyl and 3′,5′-O-L-divalinyl prodrugs.

  本发明涉及2'-脱氧-β-L-胸苷、2'-脱氧-β-L-尿苷和2'-脱氧-β-L-胞苷的合成，以及它们的衍生物，如3'-O-酰基或3',5'-O-二酰基前药，包括3'-O-L-氨基酰和3',5'-O-L-二氨基酰前药，特别是3'-O-L-缬氨酰和3',5'-O-L-二缬氨酰前药。
• Methods of treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides
  申请人：——

  公开号：US20020035085A1

  公开（公告）日：2002-03-21

  A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.

  一种治疗感染乙型肝炎的宿主的方法和组合物，包括给予所述2'-脱氧-β-L-赤霉糖核苷或其药用可接受的盐或前药的有效乙型肝炎治疗剂量。
• Radical transformations of nucleosides with (Me3Si)3SiH. Generation of a C-1’ radical through 1,2-migration of an acyloxy group
  作者：T. Gimisis、G. Ialongo、M. Zamboni、C. Chatgilialoglu

  DOI：10.1016/00404-0399(50)1340-n

  日期：1995.9

  A number of nucleoside substrates has been reduced under free radical conditions with tris(trimethylsilyl)silane. In one case a novel type of a β-(acyloxy)alkyl radical rearrangement has been observed, which leads through the generation of a C-1’ radical species to the stereoselective preparation of an α-ribonucleoside. The rate of the above 1,2-migration has been estimated, and a comparison with previously

  在自由基条件下，三（三甲基甲硅烷基）硅烷可还原许多核苷底物。在一种情况下，已经观察到新型的β-（酰氧基）烷基自由基重排，其导致C-1'自由基种类的产生导致α-核糖核苷的立体选择性制备。估计了上述1,2-迁移的速率，并与先前报告的结果进行了比较。
• &bgr;-L-2'-deoxy-nucleosides for the treatment of hepatitis B
  申请人：Novirio Pharmaceuticals Limited

  公开号：US06444652B1

  公开（公告）日：2002-09-03

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予有效量的抗HBV生物活性2'-脱氧-β-L-核糖呋喃核苷或其药物可接受的盐或前药，其中2'-脱氧-β-L-核糖呋喃核苷的化学式为：其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE是一种可以选择性取代的嘌呤或嘧啶碱基。2'-脱氧-β-L-核糖呋喃核苷或其药物可接受的盐或前药可以单独或与另一种2'-脱氧-β-L-核糖呋喃核苷或其他抗乙型肝炎药物联合使用。